What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.

In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...

In 2019, BMS made a big bet on Sotyktu by deciding to keep the then-pipeline asset despite its pending acquisition of Celgene. Based on that decision, BMS sold its mega-blockbuster Otezla to Amgen for ...

Over 8 million adults in the U.S. experience plaque psoriasis — a chronic autoimmune disease that causes painful, raised, scaly spots on the skin. People with plaque psoriasis often employ a host of ...

Plaque psoriasis, the most common form of psoriasis, affects approximately 80% to 90% of patients with psoriasis and is characterized by well-defined, erythematous plaques. Other forms of the disease ...

Psoriasis is associated with an increased prevalence of high-risk coronary plaques and risk of future cardiovascular events. In a retrospective observational study, lipid rich necrotic core (LRNC), a ...

Portia has not taken Sotyktu. Portia Brown* has long been drawn toward helping people cope with challenges. Since volunteering as a college student to work with her peers to educate them about sexual ...

Bristol Myers Squibb is bringing in yet another A-lister to support its ongoing plaque psoriasis campaign. The pharma giant recently added actress, writer and producer Mindy Kaling to the SO, Have You ...